CLDX

Celldex Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-25

Figures on this page computed 2026-11-08 12:48 UTC

Last close

29.87USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-02-25

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
-57.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
-16748.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
-13829.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
0.004Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.12 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.25x

2.11x

2.07x

1.02x

1.10x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-25

Sales0.25x
Its own average over 10 years, 6.3M.
Profit2.11x
Its own average over 10 years, -122.4M.
Free cash flow2.07x
Its own average over 10 years, -103.3M.
Debt1.02x
Its own average over 10 years, 2.3M.
Price1.10x
Its own average over 11 years, 27. Market data, 2026-11-06

Profit is furthest from its own average, at 2.11 times.

Sales is 0.25 times its own 10-year average; Profit is 2.11 times its own 10-year average; Free cash flow is 2.07 times its own 10-year average; Debt is 1.02 times its own 10-year average; Price is 1.10 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-25

Sales against its own 10-year average0.25
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
The filing itself
Profit against its own 10-year average2.11
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
The filing itself
Free cash flow against its own 10-year average2.07
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
The filing itself
Debt against its own 10-year average1.02
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
The filing itself
Price against its own 11-year average1.10Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD